Biomedical Technologies enhances lipoprotein manufacturing capabilities
The company, now part of Alfa Aesar, has doubled its ultracentrifuge capacity
Biomedical Technologies (BT) has doubled its ultracentrifuge capacity, enhancing manufacturing capabilities for custom products in response to market demand.
Preparative ultracentrifuges are used in biology for gradient separations, where the molecules in a sample are separated using a substance of graduated density, such as salt gradients for proteins. The process is often gradual and involves many sequential steps to obtain the desired gradient. BT is now able to double its lipoprotein manufacturing capability and significantly reduce lead times for both standard and custom products.
The lipoprotein manufacturing process is now 24 hours a day, 7 days a week to meet customers' demands.
Kristy McGuire, Laboratory Manager, commented: 'We are committed to our customers and believe that investing in the second ultracentrifuge will enhance our manufacturing capabilities and reduce the lead time on custom products, ultimately resulting in our customers receiving a first class service that exceeds their expectations.'
